These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 12398954)
1. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ; Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954 [TBL] [Abstract][Full Text] [Related]
2. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. Blankenship JC; Tasissa G; O'Shea JC; Iliadis EA; Bachour FA; Cohen DJ; Lui HK; Mann T; Cohen E; Tcheng JE; J Am Coll Cardiol; 2001 Sep; 38(3):653-8. PubMed ID: 11527612 [TBL] [Abstract][Full Text] [Related]
3. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884 [TBL] [Abstract][Full Text] [Related]
4. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
5. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial. Blankenship JC; Sigmon KN; Pieper KS; O'Shea C; Tardiff BE; Tcheng JE; Am J Cardiol; 2001 Nov; 88(9):969-73. PubMed ID: 11703991 [TBL] [Abstract][Full Text] [Related]
6. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034 [TBL] [Abstract][Full Text] [Related]
7. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
14. Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). Teirstein PS; Kao J; Watkins M; Tannenbaum MA; Laufer N; Chang M; Mehran R; Dangas G; Russell ME; Ellis SG; Stone GW Am J Cardiol; 2005 Aug; 96(4):500-5. PubMed ID: 16098300 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748 [TBL] [Abstract][Full Text] [Related]
16. Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group. Khan MA; Liu MW; Chio FL; Yates VB; Chapman GD; Misra VK; Sweeney A; Dean LS Catheter Cardiovasc Interv; 2001 Jan; 52(1):40-4. PubMed ID: 11146520 [TBL] [Abstract][Full Text] [Related]
17. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346 [TBL] [Abstract][Full Text] [Related]
18. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Ibbotson T; McGavin JK; Goa KL Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745 [TBL] [Abstract][Full Text] [Related]
19. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365 [TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]